Vivaldi Biosciences is developing vaccines for protection against epidemic and pandemic viral respiratory diseases using its Delta NS1 vector and innovative cell-based production technologies.
Vivaldi’s DeltaFLU universal influenza vaccine is in Phase 2 clinical development. Its Delta-19 universal influenza/Covid-19 vaccine will enter clinical trials in 2021.
Delta NS1 is a versatile and robust technology platform for self-adjuvanting vaccines administered by nasal spray. Delta NS1 is a replication-deficient vaccine vector based on a genetically modified, safely attenuated influenza virus strain. Delta NS1-based vaccines have the unique ability to rapidly induce interferon, generating protection against circulating viruses entering the nasal passages, and activating systemic antibody and cell-based protective immunity.
Location: United States, Colorado, Fort Collins
Member count: 11-50
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | Bay City C... | baycitycap... |